Related Experiment Video

Updated: Apr 3, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.4K

Advancements and Applications of Artificial Intelligence in Hypertrophic Cardiomyopathy: A Comprehensive Review

Huanhuan Ma1,2, Jing Li1, Shengjun Ta1

  • 1Department of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical University, 710032 Xi'an, Shaanxi, China.

Reviews in Cardiovascular Medicine
|April 2, 2026
PubMed

Insights

Artificial intelligence (AI) offers new ways to manage hypertrophic cardiomyopathy (HCM), a heart condition affecting adolescents. AI integrates data for better diagnosis and personalized treatment, moving towards data-driven precision medicine.

Area of Science:

  • Cardiology
  • Medical Informatics
  • Biomedical Engineering

Background:

  • Hypertrophic cardiomyopathy (HCM) is a prevalent cardiovascular disease and a significant cause of sudden cardiac death in adolescents.
  • The condition presents complex challenges in diagnosis, prognosis, and management due to its varied presentation and clinical progression.

Purpose of the Study:

  • To review the current applications of artificial intelligence (AI), machine learning (ML), and deep learning (DL) in hypertrophic cardiomyopathy (HCM) data analytics.
  • To examine methodological advancements and clinical implementations of AI in HCM.
  • To explore how AI can facilitate a shift towards data-driven paradigms in HCM diagnosis and management.

Main Methods:

  • Systematic review of AI applications in HCM data analytics.
  • Focus on integration of clinical and imaging data (echocardiography, ECG, CMR) using AI/ML/DL.
  • Analysis of challenges including data standardization, model interpretability, and privacy.

Main Results:

  • AI technologies are poised to transform the clinical management of HCM by integrating diverse data sources.
  • AI enables comprehensive risk assessment and personalized treatment strategies for HCM patients.
  • AI holds potential for timely and accurate diagnoses, advancing precision medicine in HCM.

Conclusions:

  • AI-based approaches show significant promise in revolutionizing HCM management.
  • Addressing challenges in data standardization, interpretability, and privacy is crucial for AI implementation.
  • AI facilitates a transition to data-driven precision medicine for individualized HCM patient care.

Keywords:
artificial intelligenceclinical managementelectrocardiographygeneshypertrophic cardiomyopathyimaging

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.4K
An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.3K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
718
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
647
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
769
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
580
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
818